Semin Respir Crit Care Med 2000; 21(4): 341-348
DOI: 10.1055/s-2000-9858
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Acinetobacter

James J. Rahal, Carl Urban
  • The New York Hospital Medical Center of Queens, Flushing, New York and Sanford and Joan Weill Medical College, Cornell University, New York, New York
Further Information

Publication History

Publication Date:
31 December 2000 (online)

ABSTRACT

Members of the genus Acinetobacter are oxidase negative, aerobic Gram-negative coccobacilli, which have evolved taxonomically from former strains of the Mima-Herrelia group. Their natural habitat is human skin and mucous membranes, water, soil, vegetation, and sewage. The most common multiresistant nosocomial pathogen among 19 genospecies is the A. calcoaceticus-baumannii complex (A. baumannii). This species is not a common component of normal human acinetobacter colonization, and its ecological origin remains unknown. Outbreaks of nosocomial acinetobacter infection are due to spread of one or a few clones among patients, personnel, and the inanimate hospital environment. Thus, strict implementation of infection control procedures is the major technique for prevention and suppression of such outbreaks. Surveillance cultures of personnel and the environment; molecular genotyping of isolates; cohorting of colonized or infected patients and staff; and topical application of polymyxin B to colonized wounds have been used to enhance standard infection control procedures. Antimicrobial resistance to beta lactam antibiotics in Acinetobacter is due primarily to a combination of chromosomal beta lactamase production and reduced outer membrane permeability. Carbapenem resistance is an increasing phenomenon and restriction of late-generation cephalosporin and carbapenem utilization should be considered in outbreak control. Effective therapy of multiresistant Acinetobacter infection may require a variety of potentially synergistic antibiotic combinations.

REFERENCES

  • 1 Streckenberger P C, von Graevenitz A. Acinetobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative gram-negative rods. In: Murray PR, ed. Manual of Clinical Microbiology 7th ed. Washington, DC 1999: 539-560
  • 2 API 20 Base NE® Identification system for non-enteric gram-negative rods. Hazelwood, MO: bioMérieux Vitek Inc. 1998: 1-9
  • 3 Editorial. Bacteria of the tribe Mimeae .  JAMA. 1963;  186 947
  • 4 Taplin D, Rebell G, Zaias N. The human skin as a source of Mima-Herrelia infections.  JAMA . 1963;  186 166-168
  • 5 Grehn M, von Graevenitz A. Search for Acinetobacter calcoaceticus, subsp. anitratus: Enrichment of fecal samples.  J Clin Microbiol . 1978;  8 342-343
  • 6 Rosenthal S, Tager T B. Prevalence of gram-negative rods in the normal pharyngeal flora.  Ann Intern Med . 1975;  83 355-357
  • 7 Kozub W R, Bucolo S, Sami A W, Chatman C E, Pribor H C. Gonorrhea-like urethritis due to Mima polymorpha var.  oxidans Arch Intern Med . 1968;  122 514-516
  • 8 Alami S Y, Riley Jr D H. Infections caused by Mimeae, with special reference to Mima polymorpha: A review.  Am J Med Sci . 1966;  252 537-544
  • 9 Shea D W, Phillips J H. Mimeae endocarditis; a clinical syndrome?.  Am J Med Sci . 1966;  252 201-205
  • 10 Hirsch S R, Koch M L. Herellea (Bacterium anitratum) endocarditis.  JAMA . 1964;  187 148-150
  • 11 Daly A K, Postic B, Kass E H. Infections due to organisms of the genus Herellea Arch Intern Med .  1962;  110 580-591
  • 12 Berezin-Bergogne E, Towner K J. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features.  Clin Microbiol Rev . 1996;  9 148-165
  • 13 Anstey N M, Currie B J, Withnall K M. Community-acquired Acinetobacter pneumonia in the northern territory of Australia.  Clin Infect Dis . 1992;  14 83-91
  • 14 Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: Comparison of phenotypic and genotypic identification methods.  J Clin Microbiol . 1997;  35 2819-2825
  • 15 Berlau J, Aucken H, Malnick H, Pitt T. Distribution of Acinetobacter species on skin of healthy humans.  Eur J Clin Microbiol Infect Dis . 1999;  18 179-183
  • 16 Sader H S, Mendes C F, Pignatari A C, Pfaller M A. Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in Sao Paulo, Brazil.  Clin Infect Dis . 1996;  23 631-634
  • 17 Scerpella E G, Wanger A R, Armitige L, Anderlini P, Ericsson C D. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: Results of the case-control and molecular epidemiologic investigations.  Infect Control Hosp Epidemiol . 1995;  16 92-97
  • 18 McDonald L C, Walker M, Carson L. Outbreak of Acinetobacter spp. bloodstream infections in a nursery associated with contaminated aerosols and air conditioners.  Pediatr Infect Dis J . 1998;  17 716-722
  • 19 Patterson J E, Vecchio J, Pantelick E L, Farrel P, Mazon D, Zervos M J, Hierholzer W J. Association of contaminated gloves with transmission of Acinetobacter calcoaceticus var. anitratus in an intensive care unit.  Am J Med . 1991;  91 479-483
  • 20 Tankovic J, Legrand P, DeGatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods.  J Clin Microbiol . 1994;  32 2677-2681
  • 21 Go E S, Urban C, Burns J. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.  Lancet . 1994;  344 1329-1332
  • 22 Seifert H, Schulze A, Baginski R, Pulverer G. Comparison of four different methods for epidemiologic typing of Acinetobacter baumannii J Clin Microbiol .  1994;  32 1816-1819
  • 23 Seifert H, Gerner-Smidt P. Comparison of ribotyping and pulsed-field gel electrophoresis for molecular typing of Acinetobacter isolate.  J Clin Microbiol . 1995;  33 1402-1407
  • 24 Snelling A M, Gerner-Smidt P, Hawkey P M. Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak.  J Clin Microbiol . 1996;  34 1193-1202
  • 25 Timsit J F, Garrait V, Misset B, Goldstein F W, Renaud B, Carlet J. The digestive tract is a major site for Acinetobacter baumannii colonization in intensive care unit patients.  J Infect Dis . 1993;  168 1336-1337
  • 26 Corbella X, Pujol M, Ayats J. Relevance of digestive tract colonation in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii Clin Infect Dis .  1996;  23 329-334
  • 27 Lortholary O, Fagon J Y, Hoi A B, Mahieu G, Gutmann L. Colonization by Acinetobacter baumannii in intensive-care-unit patients.  Infect Control Hosp Epidemiol . 1998;  19 188-190
  • 28 Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii <~>Clinical features, epidemiology, and predictors of mortality.  Medicine . 1995;  74 340-349
  • 29 Tilley P AG, Roberts F J. Bacteremia with acinetobacter species: Risk factors and prognosis in different clinical settings.  Clin Infect Dis . 1994;  18 896-900
  • 30 Cisneros J M, Reyes M J, Pachon J. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings and prognostic features.  Clin Infect Dis . 1996;  22 1026-1032
  • 31 Shlaes D M, Gerding D N, John Jr F J. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals.  Infect Control Hosp Epidemiol . 1997;  18 275-291
  • 32 Flaherty J P, Weinstein R A. Nosocomial infection caused by antibiotic-resistant organisms in the intensive care unit.  Infect Control Hosp Epidemiol . 1996;  17 236-248
  • 33 Rahal J J, Urban C, Horn D. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA .  1998;  280 1233-1237
  • 34 Tankovic J, Legrand P, DeGatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods.  J Clin Microbiol . 1994;  32 2677-2681
  • 35 Zuccotti G, Currie B P. Molecular epidemiology of multiple antibiotic resistant (MAR) Acinetobacter anitratus isolates at a single hospital. Washington, DC: Society for Healthcare Epidemiology of America 1998 Abstract #59
  • 36 Zuccotti G, Currie B P. An investigation of the relationship of colonizing and infecting nosocomial Acinetobacter anitratus isolates. Washington, DC: Society for Healthcare Epidemiology of America 1998 Abstract #56
  • 37 McDonald L C, Banerjee S N, Jarvis W R, NISS Hospital Infections Program. Seasonal variation of Acinetobacter spp. infections reported to the National Nosocomial Infection Surveillance (NNIS) system: 1987-1996. Washington, DC: Society for Healthcare Epidemiology of America 1998 Abstract #55
  • 38 Christie C, Mazon D, Hierholzer W, Patterson J E. Molecular heterogeneity of Acinetobacter baumannii isolates during seasonal increase in prevalence.  Infect Control Hosp Epidemiol . 1995;  16 590-594
  • 39 Jawad A, Seifert H, Snelling A M, Heritage J, Hawkey P M. Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates.  J Clin Microbiol . 1998;  36 1938-1941
  • 40 Brun-Buisson C, Legrand P. Can topical and nonabsorbable antimicrobials prevent cross-transmission of resistant strains in ICUs?.  Infect Control Hosp Epidemiol . 1994;  15 447-455
  • 41 D'Amico Roberto, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: Systematic review of randomised controlled trials.  Br Med J . 1998;  316 1275-1285
  • 42 Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species.  Antimicrob Agents Chemother . 1993;  37 750-773
  • 43 Perilli M, Felici A, Oratore A, Cornaglia G, Bonfiglio G, Rossolini G M, Amicosante G. Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates.  Antimicrob Agents Chemother . 1996;  40 715-719
  • 44 MacGowan A P, Bowker K E, Bedford K A, Holt H A, Reeves D S, Hedges A. The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins.  J Antimicrob Chemother . 1995;  35 333-337
  • 45 Vahaboglu H, Ozturk R, Aygun G. Widespread Detection of PER-1 type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: A nationwide multicenter study.  Antimicrob Agents Chemother . 1997;  41 2265-2269
  • 46 Daniel F, Hall L M, Gur D, Akalin H E, Livermore D M. Transferable production of PER-1 beta lactamase in Pseudomonas aeruginosa J Antimicrob Chemother .  1995;  35 281-294
  • 47 Livermore D M. β-lactamase-mediated resistance and opportunities for its control.  J Antimicrob Chemother . 1998;  41(suppl D) 25-41
  • 48 Poirel L, Karim A, Mercat A, LeThomas I, Vahaboglu H, Richard C, Nordmann P. Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France.  J Antimicrob Chemother . 1999;  43 157-165
  • 49 Weinbren M J, Johnson A P, Kaufmann M E, Livermore D M. Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit.  J Antimicrob Chemother . 1998;  41 574-576
  • 50 Afzal-Shah M, Villar H E, Livermore D M. Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Bueonos Aires, Argentina.  J Antimicrob Chemother . 1999;  43 127-131
  • 51 Brown S, Bantar C, Young H-K, Amyes S GB. Limitation of Acinetobacter baumanni treatment by plasmid-mediated carbapenemase ARI-2.  Lancet . 1998;  351 186-187
  • 52 Sato K, Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implementation in antibiotic resistance.  J Antimicrob Chemother . 1991;  28 35-45
  • 53 Gehrlien M, Leyung H, Cullmann W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins.  Chemotherapy . 1991;  37 405-412
  • 54 Clark R B. Imipenem resistance among Acinetobacter baumanni: Association with reduced expression of a 33-36 kDa outer membrane protein.  J Antimicrob Chemother . 1996;  38 245-251
  • 55 Vila J, Ruiz J, Navia M. Spread of amikacin resistance in Acinetobacter baumanni strains isolated in Spain due to an epidemic strain.  J Clin Microbiol . 1999;  37 758-761
  • 56 Martinez J L, Alonso A, Gomez-Gomez J M, Baquero F. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?.  J Antimicrob Chemother . 1998;  42 683-688
  • 57 Hooper D C. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.  Clin Infect Dis . 1998;  27(suppl 1) S54-S63
  • 58 Pascual A, Lopez-Hernandez I, Martinez-Martinez L, Perea E J. In-vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones.  J Antimicrob Chemother . 1997;  40 140-142
  • 59 Kuck N A. In Vitro and In Vivo activities of minocycline and other antibiotics against Acinetobacter (Herellea-Mima) Antimicrob Agents Chemother .  1976;  9 493-497
  • 60 Montgomerie J Z, Pickett M J, Yoshimori R N, Chow A W, Guze L B. Susceptibility of Acinetobacter calcoaceticus var. anitratus (Herellea vaginicola) to minocycline.  Antimicrob Agents Chemother . 1976;  10 102-105
  • 61 Traub W H, Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, Genospecies 3, and Genospecies 6).  Antimicrob Agents Chemother . 1989;  33 1617-1619
  • 62 Van Ogtrop M L, Andes D, Craig W A, Vesga O. In-vivo activity of two glycylcyclines (GAR-936 and WAY 152,288) against tetracycline-sensitive and resistant bacteria. 38th Interscience Conference on Antimicrobial Agents, and Chemotherapy, San Diego 1998 Abstract F133
  • 63 Greene J N. The microbiology of colonization, including techniques for assessing and measuring colonization.  Infect Control Hosp Epidemiol . 1996;  17 114-118
  • 64 George D L, Falk P S, Wunderink R G. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling.  Am J Respir Crit Care Med . 1998;  158 1839-1847
  • 65 Luna C M, Vujacich P, Niederman M S, Vay C, Gherardi C, Matera J, Jolly E C. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.  Chest . 1997;  111 676-685
  • 66 Sanchez-Nieto J M, Torres A, Garcia-Cordoba F. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia.  Am J Respir Crit Care Med . 1998;  157 371-376
  • 67 Joshi M, Bernstein J, Solomkin J, Wester B A, Juye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam nosocomial pneumoniae study group.  J Antimicrob Chemother . 1999;  43 389-397
  • 68 Trouillet J-L, Chastre J, Vuagnat A, Joly-Guillou M-L, Combaux D, Dombret M-C, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.  AM J Respir Crit Care Med . 1998;  157 531-539
  • 69 Urban C, Go E, Mariano N, Rahal J J. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and susceptible Acinetobacter baumannii FEMS Microbiol Lett .  1995;  125 193-198
  • 70 Lipman J, Scribante J, Gous A GS, Hon H, Tshukutsoane S, the Baragwanath Ciprofloxacin Study Group. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis.  Antimicrob Agents Chemother . 1998;  42 2235-2239
  • 71 Kashuba A DM, Nafziger A N, Drusano G L, Bertino J S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.  Antimicrob Agents Chemother . 1999;  43 623-629
  • 72 Anstey N M. Use of cefotaxime for treatment of acinetobacter infections.  Clin Infect Dis . 1992;  15 374-375
  • 73 Carmeli Y, Troillet N, Eliopoulos G M, Samore M H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents.  Antimicrob Agents Chemother . 1999;  43 1379-1382
  • 74 Chini N X, Scully B, Della-Latta P. In-vitro synergy of polymyxin B with imipenem and other antimicrobial agents against Acinetobacter, Klebsiella and Pseudomonas species. 38th Interscience Conference on Antimicrobial Chemotherapy. Sept. 24-27, 1998, San Diego, CA, Abstract E56.
  • 75 Hogg G M, Barr J G, Webb C H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii J Antimicrob Chemother .  1998;  41 494-495
  • 76 Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combination of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii J Antimicrob Chemother .  1998;  42 270-271
  • 77 Wood C A, Reboli A C. Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus J Infect Dis .  1993;  168 1602-1603
  • 78 Urban C, Go E, Mariano N, Berger B J, Avraham I, Rubin D, Rahal J J. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus J Infect Dis .  1993;  167 448-451
  • 79 Jimenez-Mejias M E, Pachon J, Becerril B, Palomino-Nicas J, Rodriquez-Cobaco A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.  Clin Infect Dis . 1997;  24 932-935
  • 80 Corbella X, Ariza J, Ardanuy C. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii J Antimicrob Chemother .  1998;  42 793-802
  • 81 Levin A S, Barone A A, Penco J. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis .  1999;  28 1008-1011
  • 82 Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.  Clin Infect Dis . 1999;  28 916-917
  • 83 Wolff M, Joly-Guillou M L, Farinotti R, Carbon C. In-Vivo efficacies of combinations of β-lactams, β-lactamse inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.  Antimicrob Agents Chemother . 1999;  43 1406-1411